Working… Menu

Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02100969
Recruitment Status : Active, not recruiting
First Posted : April 1, 2014
Last Update Posted : March 2, 2018
CSL Behring
Information provided by (Responsible Party):
Mazen Dimachkie, MD, University of Kansas Medical Center

Brief Summary:
The purpose of this study is to determine whether Hizentra is a safe and effective treatment for people with myasthenia gravis (MG).

Condition or disease Intervention/treatment Phase
Myasthenia Gravis Drug: HIZENTRA ® Phase 2

Detailed Description:

Myasthenia gravis (MG) is a rare autoimmune disorder which causes the muscles to become weak because the immune system attacks the connection between the nerves and the muscles.

Hizentra is a subcutaneous (under the skin) immunoglobin (SCIg). An immunoglobin is a blood protein. Hizentra is being studied for the treatment of patients with MG. Hizentra is administered by an injection into the skin through a portable infusion pump, which may be easier for patients to administer than the current treatments.

Participants will be asked to complete 9 clinic visits and 3 telephone calls. It could take up to 30 weeks to complete all study visits.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
Actual Study Start Date : May 2015
Actual Primary Completion Date : November 2017
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Hizentra
Hizentra is a subcutaneous (under the skin) immunoglobin (SCIg). Participants will receive weekly Hizentra. Dose and rate depend on the visit and how each participant tolerates the drug. Max flow rate not to exceed 100 mL per hour.
Other Name: Immune Globulin Subcutaneous (Human), 20% Liquid

Primary Outcome Measures :
  1. Change in MG severity [ Time Frame: Change from Baseline to Week 12 ]
    Change will be measured using the Quantitative Myasthenia Gravis (QMG) Score for Disease severity. The QMG is a validated clinical composite scale.

Secondary Outcome Measures :
  1. Efficacy of SCIg in MG [ Time Frame: Change from Baseline to Week 12 ]
    Composite measure of scores from measurement scales including Myasthenia Gravis-specific Activities of Daily Living scale (MG-ADL), MG Quality of Life (QOL)-15, MG composite score, and Treatment Satisfaction Questionnaire for Medication (TSQM)

  2. Safety and tolerability of SCIg in people with MG [ Time Frame: Change from Week -12 to Week 12 ]
    Measure safety profile between intravenous and subcutaneous treatment phases as measured by changes in routine safety laboratory tests. Lab tests used to determine outcome include CBC, differential and comprehensive chemistry profile.

  3. Number of Participants with Serious and Non-Serious Adverse Events [ Time Frame: Up to 16 Weeks ]
    Safety of SCIg in MG patients measured according to adverse event experienced by trial participants

  4. Effect of SCIg on IgG antibody levels [ Time Frame: Change from Week -12 to Week 12 ]
    Measure IgG level between intravenous and subcutaneous study phases

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must have MGFA MG grades 2, 3, or 4 generalized MG, according to the MGFA classification system
  • Elevated AChR or MuSK Ab
  • Patient's signs and symptoms should not be better explained by another disease process
  • IVIg maintenance dose of 0.2 to 2 gm/kg/4 weeks or equivalent dose administered every 2-4 weeks
  • Stable IVIg for at least 3 cycles
  • Able to complete the study and return for follow-up visits
  • Able to give written informed consent before participating in the study

Exclusion Criteria:

  • History of chronic degenerative, psychiatric, or neurologic disorder other than MG that can produce weakness or fatigue
  • Other major chronic or debilitating illnesses within six months prior to study entry
  • Female patients who are premenopausal and are (a) pregnant, (b) breastfeeding, or (c) not using an effective method of double barrier birth control
  • Altered levels of consciousness, dementia, or abnormal mental status
  • Thymectomy in the previous three months
  • History of renal insufficiency or liver disease
  • Skin disease that would interfere with assessment of injection site reaction
  • History of severe reactions to IVIg or SCIg
  • Participation in a research study within the last 3 months
  • Treatment with rituximab or other biologics within 12 months of study entry
  • Unable to provide informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02100969

Layout table for location information
United States, Arizona
Phoenix Neurological Associates
Phoenix, Arizona, United States, 85018
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
United States, New York
University at Buffalo
Buffalo, New York, United States, 14203
United States, Texas
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Canada, Ontario
University of Toronto
Toronto, Ontario, Canada
Sponsors and Collaborators
Mazen Dimachkie, MD
CSL Behring
Layout table for investigator information
Principal Investigator: Mazen M Dimachkie, MD University of Kansas Medical Center

Layout table for additonal information
Responsible Party: Mazen Dimachkie, MD, Professor, University of Kansas Medical Center Identifier: NCT02100969     History of Changes
Other Study ID Numbers: STUDY00001041
First Posted: April 1, 2014    Key Record Dates
Last Update Posted: March 2, 2018
Last Verified: March 2018
Keywords provided by Mazen Dimachkie, MD, University of Kansas Medical Center:
autoimmune neuromuscular disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Myasthenia Gravis
Muscle Weakness
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Pathologic Processes
Signs and Symptoms
Autoimmune Diseases of the Nervous System
Neuromuscular Junction Diseases
Neuromuscular Diseases
Autoimmune Diseases
Immune System Diseases
Immunoglobulin G
Immunologic Factors
Physiological Effects of Drugs